A Novel Probiotic Strain with Dynamic Gut-Brain and Upper Respiratory Benefits
Probiotic microorganisms have a long history of safe use and have been documented for various health benefits. Many strains of lactic acid bacteria (LAB) from the genera of Lactobacillus have been identified to possess probiotic properties. They have been much emphasized for their roles to regulate gut well-being. But recent evidence has illustrated the potential of LAB for brain health, ranging from neurodegenerative diseases to stress, memory and cognition.
In this webinar you’ll learn about Lactobacillus plantarum DR7, a cow’s milk isolate from Penang, Malaysia, which has shown a reversal of symptoms associated with Alzheimer’s Disease in a fruit fly model, accompanied by distinct changes of gut microbiota profiles. In aging rats, DR7 has shown improved stress and anxiety symptoms, accompanied by improved memory.
The administration of DR7 for 12-weeks in stressed adults has contributed to improve stress and anxiety scores, in addition to memory and cognitive abilities, primarily via enhancement along the serotonin pathway and maintenance of the dopamine pathway.
Gut microbiota analyses of human subjects also showed correlations between changes in neurotransmitter genes and different taxonomic levels of gut microbiota along the serotonin and dopamine pathways. This evidence involving various models, strongly indicated an effect of DR7 along the gut-brain-axis.
We hope you can join us live on September 15th at 4 PM MT. If not, don’t worry, signing up will still grant you access to the webinar recording.
Dr. Barry was a Principal Advisor for NIH specializing in the commercial development of biotech start-up companies, their technologies and products. He also founded and served as president of a premier independent testing laboratory and scientific research company serving the natural products industry. Prior to that, Dr. Barry developed a natural products division for a major analytical device company where he served as vice president and chief technical officer.
Dr. Barry brings more than 18 years of strategic technical development and commercial translation of scientific products, analytical services, drug development and pre-clinical evaluation systems to his position. Prior to joining Kaneka, he cofounded and served as the president of a Massachusetts-based drug development company. Under Dr. Barry’s direction, the company identified new lead-drug candidates focusing on unmet clinical needs in several disease areas.
Dr. Barry earned his bachelor’s degree in biology from Boston College; his Ph.D. in chemistry/biochemistry from the University of Maryland; postdoctoral research in Biological Chemistry and Molecular Pharmacology at Harvard Medical School; and was a staff researcher in neuropathology at Harvard Medical School.